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In this issue of Annals of Surgical Oncology, Wasif and
coauthors report the results of a survey of 537 American
Society of Clinical Oncology (ASCO) members that shows
only 23% of surgeons and medical oncologists, and only
15% of radiation oncologists, ‘‘always’’ perform an axillary
dissection for the finding of micrometastases in the sentinel
node (SN).1 This practice is contrary to ASCO guidelines
that state axillary dissection is the standard management of
micrometastases in the SN.2 Documentation of a major
deviation from guidelines is important, although it is pos-
sible to quibble with some of the specifics of this article.
After all, the ASCO guidelines were published in 2005, and
our knowledge regarding the SN procedure has increased
exponentially since that time; it is not unreasonable to
conclude that part of the reason the guidelines are not
followed is because they are out of date. In addition, the
wording of the survey question as ‘‘always’’ was unfortu-
nate, since virtually nothing in breast cancer surgery is
absolute. The use of the word ‘‘usually’’ might have pro-
vided a more accurate picture of clinical practice.
However, to focus on these points is to miss the bigger
questions: Why is there so much disagreement about
appropriate practice? What have we learned about mi-
crometastases and how should we deal with them?
Micrometastases are an unintended consequence of the
more detailed tissue processing that is possible when
examining a small number of sentinel lymph nodes rather
than an entire axillary dissection specimen. Giuliano et al.
first reported the increased frequency of identification of
small metastases in 1995, with subsequent confirmation in
other reports.3 Since that time, a key question for the
clinical community has been: ‘‘Is axillary dissection
necessary for SN micrometastases?’’ The benefit of axillary
dissection is dependent on the likelihood of finding addi-
tional nodal metastases. Perhaps surprisingly, 12–20% of
patients with isolated tumor cells or micrometastases in the
SN included in two recent meta-analyses had additional
nodal involvement, and in a substantial number of cases the
additional metastases were macrometastases.4,5 These
studies clearly make the point that a small amount of tumor
in the SN does not indicate that disease in non-SNs will
also be low volume. These results are clearly sufficient to
justify axillary dissection if the finding of additional
metastases will change the systemic therapy administered.
An example is the patient with an ER/PR-positive, HER2-
negative, T1 tumor who might be considered suitable for
endocrine therapy alone with a single micrometastases, but
who, with additional micrometastases or a macrometasta-
sis, would receive chemotherapy as well. More commonly,
however, decisions about systemic therapy are not depen-
dent on the presence of additional nodal metastases,
leaving local control or a survival benefit as the rationale
for axillary dissection. Many years ago, the National Sur-
gical Adjuvant Breast and Bowel Project (NSABP) BO4
trial demonstrated that only about 40% of nodal metastases
result in clinically evident axillary recurrence in patients
treated with surgery alone.6 The tangent field radiotherapy
(RT) that is part of breast-conserving therapy includes a
substantial part of the low axilla and can be anticipated to
reduce this risk further. This is borne out by clinical out-
comes in patients with SN involvement who have not had
an axillary dissection, where axillary recurrence is
uncommon.7 As a result, it is difficult to argue that most
women need an axillary dissection to maintain local
control.
What about survival? The Early Breast Cancer Trialists
Collaborative Group (EBCTCG) overview indicates that
differences in local control of greater than 10–20% at
5 years of follow-up translate into significant differences in
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survival at 15 years.8 Although this concept was demon-
strated for recurrences in the breast or on the chest wall
postmastectomy, there is no reason to believe that recur-
rence in the axilla would not be equally important.
However, to reach this level of difference in local recur-
rence by omitting axillary dissection, the risk of additional
axillary nodal involvement would need to exceed 30%,
something that is infrequently seen in patients with
micrometastatic disease in the SN. Based on these points, I
must conclude that axillary dissection appears to be of little
benefit to the majority of patients with micrometastases
beyond providing additional prognostic information.
However, what is special about micrometastases? The
0.2-mm threshold chosen to define a micrometastases is an
arbitrary one, and the reproducibility of measurement of
the size of nodal metastases is uncertain.9 The question
asked here regarding the need for axillary dissection for
micrometastases is equally applicable to macrometastases
in the SN, and it is particularly likely to be asked when
macrometastases are not detected by intraoperative frozen
section. At present, the decision about whether to proceed
with an axillary dissection is made based on the risk of
additional nodal metastases predicted by a variety of no-
mograms and on the level of patient and physician
preference for or against axillary dissection.10,11 It would
be preferable to have an actual answer to the question of
whether elimination of axillary dissection was harmful to
patients. The American College of Surgeons (ACOSOG)
Z11 trial attempted to do just that by randomizing women
with hematoxylin- and eosin-detected axillary nodal
metastases to a completion dissection or no further axillary
treatment. This study was opened in 1999 and closed in
2004 after accruing only 891 of the 1900 patients needed to
identify a 5% or greater survival difference with axillary
dissection. The Z11 trial was clearly ahead of its time.
Many surgeons were unwilling to randomize patients
because at that time, they were certain it was unethical to
consider eliminating axillary dissection. According to the
survey presented by Wasif et al., however, times have
changed.1 As a result of our unwillingness as a clinical
community to support the Z11 trial, we make the decision
about axillary dissection based on retrospectively derived
nomograms coupled with clinical judgment. This is a tra-
ditional surgical approach that we seem to be comfortable
with, but it does not necessarily represent the best approach
to controversies in management. The resolution of impor-
tant clinical questions and the creation of paradigm shifts
require clinical trials with the vision to address the big
picture, and these trials are often the most difficult for both
surgeons and their patients to participate in. It is worth
thinking about how different breast-conserving therapy
might look today if the NSABP B06 trial had not com-
pleted its accrual of a population of women of varying ages
and tumor features. Although it is impossible to know for
certain, I suspect that breast conservation would be con-
sidered an appropriate strategy for small favorable cancers,
with mastectomy reserved for the remainder.
The appropriate management of the axilla in the era of
SN biopsy in conjunction with the improved systemic
therapy available today remains the big, unanswered
question in the surgical therapy of breast cancer. As a
community of surgeons, we failed to address this question
the first time around; the consequences of that failure are
evident every time we discuss this issue with our patients.
Should the opportunity for participation in another trial
arise, let us hope that we are all not only older at that
moment, but wiser as well.
REFERENCES
1. Wasif N, Ye X, Giuliano AE. Survey of ASCO members on
management of sentinel node micrometastases in breast cancer:
variation in treatment recommendations according to specialty.
Ann Surg Oncol. 2009. DOI: 10.1245/s10434-009-0549-7.
2. Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bod-
urka DC, Burstein HJ, et al. American Society of Clinical Oncology
guideline recommendations for sentinel lymph node biopsy in
early-stage breast cancer. J Clin Oncol. 2005;23:7703–20.
3. Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW,
Krasne DL. Improved axillary staging of breast cancer with
sentinel lymphadenectomy. Ann Surg. 1995;222:394–9 (discus-
sion 399–401).
4. Cserni G, Gregori D, Merletti F, Sapino A, Mano MP, Ponti A,
et al. Meta-analysis of non-sentinel node metastases associated
with micrometastatic sentinel nodes in breast cancer. Br J Surg.
2004;91:1245–52.
5. van Deurzen CM, de Boer M, Monninkhof EM, Bult P, van der
Wall E, Tjan-Heijnen VC, et al. Non-sentinel lymph node
metastases associated with isolated breast cancer cells in the
sentinel node. J Natl Cancer Inst. 2008;100:1574–80.
6. Fisher B, Redmond C, Fisher ER, Bauer M, Wolmark N,
Wickerham DL, et al. Ten-year results of a randomized clinical
trial comparing radical mastectomy and total mastectomy with or
without radiation. N Engl J Med. 1985;312:674–81.
7. Park J, Fey JV, Naik AM, Borgen PI, Van Kee KJ, Cody HS 3rd.
A declining rate of completion axillary dissection in sentinel
lymph node-positive breast cancer patients is associated with the
use of a multivariate nomogram. Ann Surg. 2007;245:462–8.
8. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E,
et al. Effects of radiotherapy and of differences in the extent of
surgery for early breast cancer on local recurrence and 15-year
survival: an overview of the randomised trials. Lancet.
2005;366:2087–106.
9. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG,
et al. editors. AJCC Cancer Staging Manual. 6th ed., New York:
Springer-Verlag, 2002:221–40.
10. Gur AS, Unal B, Johnson R, Ahrendt G, Bonaventura M, Gordon
P, et al. Predictive probability of four different breast cancer
nomograms for nonsentinel axillary lymph node metastasis in
positive sentinel node biopsy. J Am Coll Surg. 2009;208:229–35.
11. Van Zee KJ, Manasseh DM, Bevilacqua JL, Boolbol SK, Fey JV,
Tan LK, et al. A nomogram for predicting the likelihood of
additional nodal metastases in breast cancer patients with a
positive sentinel node biopsy. Ann Surg Oncol. 2003;10:1140–51.
2430 M. Morrow
